Perrigo Company PLC is producing a launch supply of the first OTC oral contraceptive approved in the US while also continuing the “supply chain reinvention” it began earlier in 2023 as the current phase of its operations and portfolio overhaul.
The firm on 8 August, announcing its first results with Patrick Lockwood Taylor at the helm, reported $1.2bn second-quarter net sales, up 6.4%, or 6.6% on a constant currency basis, while the organic measure – excluding additions, divestments or other changes since the prior-year period – was 0.8% growth after a 2
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?